6086 (6086) Fair Value & Analysis

Healthcare · Market cap HK$914M

6 6086 6086 · HK

PriceHK$0.6600

Fair ValueHK$0.3400

Upside-48.5%

Quality38/100

Watch 6086 for free — get notified when fair value or trend changes. Watch for free

Evidence: High Range HK$0.1700 – HK$0.3500

Fair value as of: Jul 2, 2026

From 24 valuation models · updated today

Share price −35.3% over the past month.

Price vs Fair Value (12 months)

12‑month range HK$0.6600 – HK$4.88 · fair‑value band HK$0.1700 – HK$0.3500 · the HK$0.6600 price screens above the HK$0.3400 fair value. As of Jul 2, 2026.

✦ Which stocks are undervalued right now? Check free Discover now →

Analysis

6086 (6086) currently trades at HK$0.6600, while our model-based Fair Value estimate is HK$0.3400 — implying the stock looks roughly 48.5% overvalued today. We read business quality at 38/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).

Over the trailing twelve months, 6086 generated revenue of HK$3.5B at a net margin of 0.3%. Revenue grew 46.8% year over year. It earns a return on equity of 8.3%. The balance sheet holds a net cash position of HK$261M. Fundamentals as of Jul 2, 2026

Key figures & financial health

Revenue (TTM) HK$3.5B

Revenue growth (YoY) +46.8%

Net margin 0.3%

Return on equity 8.3%

Free cash flow HK$65.4M FY2025

P/E ratio 66.0

More key figures

Operating margin 0.0%

EPS (TTM) HK$0.0100

Net cash HK$261M FY2025

Figures from reported company fundamentals (EODHD) · as of Jul 2, 2026. TTM = trailing twelve months.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

6086 reported revenue of HK$3.5B in FY2025 versus HK$1.8B in FY2021, a compound +19.0%/yr. Reported net income was HK$11.8M in FY2025.

Revenue +19.0%/yr

FY21 HK$1.8B

FY22 HK$2.2B

FY23 HK$2.4B

FY24 HK$2.7B

FY25 HK$3.5B

Net income

FY21 −HK$304M

FY22 −HK$383M

FY23 −HK$197M

FY24 −HK$855M

FY25 HK$11.8M

Is 6086 fairly valued? → Check now

Similar stocks

6 more Pharmaceutical Retailers stocks, each showing price versus our Fair Value estimate (as of Jul 2, 2026).

Stock	Price	Fair Value	vs Fair Value
JD Health International Inc JDHIY	$5.33	$7.09	+33%
6618 6618	HK$34.16	HK$33.08	-3%
Alibaba Health Information Technology Limited ALBBY	$8.56	$6.91	-19%
0241 0241	HK$3.08	HK$2.04	-34%
Raia Drogasil S.A RADL3	R$16.79	R$20.39	+21%
Yifeng Pharmacy Chain Co 603939	¥19.75	¥29.07	+47%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks Technology Financial Services Healthcare Consumer Cyclical Consumer Defensive Communication Services Industrials Energy Basic Materials Real Estate Utilities Deeply Undervalued Stocks Undervalued Blue-Chip Stocks Undervalued Small-Cap Stocks

Frequently asked questions

Is 6086 (6086) undervalued?

As of Jul 2, 2026, our model estimates a fair value of HK$0.3400 versus a price of HK$0.6600 — about −48% (overvalued). Model-based estimate, not financial advice.

What is the fair value of 6086?

Our model-based fair value for 6086 is HK$0.3400 (as of Jul 2, 2026), built from audited fundamentals. The current price is HK$0.6600.

What is the quality score of 6086?

6086 has a Quality Score of 38/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

What is the revenue of 6086 (6086)?

6086 reported trailing-twelve-month revenue of about HK$3.5B (latest available figure, as of Jul 2, 2026).

What is the net profit margin of 6086?

The net profit margin of 6086 is about 0.3%, meaning it keeps roughly 0.3% of revenue as net income. Based on the latest reported figures.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.